From the Department of Anesthesiology and Intensive Care Medicine, University of Göttingen Medical Center, Göttingen, Germany (M.Q., M.B., L.G.) University of Michigan, Ann Arbor, Michigan (R.H.B.) Perioperative Medicine and Critical Care Research Group, Southampton NIHR Biomedical Research Centre, University Hospital Southampton/University of Southampton, Southampton, United Kingdom (M.P.W.G.) Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France (A.C.) Service of Intensive Care, Institute of Cardiology, APHP Hôpital Pitié-Salpêtrière, Paris, France (A.C.) Alma Mater Studiorum - Department of Medical and Surgical Sciences, University of Bologna, Anesthesia and Intensive Care Medicine, Policlinico di Sant'Orsola, Bologna, Italy (M.V.R., M.B.) Department of Clinical, Integrated, and Experimental Medicine (DIMES), Respiratory and Critical Care, Sant'Orsola Malpighi Hospital, Bologna, Italy (S.N.) Department of Medicine, Columbia University College of Physicians and Surgeons, and New York Presbyterian Medical Center, New York, New York (D.B.) Department of Adult Critical Care, Guy's and St. Thomas' NHS Foundation Trust, King's Health Partners, and Division of Centre of Human Applied Physiological Sciences, King's College London, London, United Kingdom (L.C., F.V.) Department of Pulmonary and Critical Care Medicine, Regions Hospital and University of Minnesota, Minneapolis/St. Paul, Minnesota (J.J.M.).
Anesthesiology. 2020 May;132(5):1257-1276. doi: 10.1097/ALN.0000000000003221.
This review focuses on the use of veno-venous extracorporeal membrane oxygenation for respiratory failure across all blood flow ranges. Starting with a short overview of historical development, aspects of the physiology of gas exchange (i.e., oxygenation and decarboxylation) during extracorporeal circulation are discussed. The mechanisms of phenomena such as recirculation and shunt playing an important role in daily clinical practice are explained.Treatment of refractory and symptomatic hypoxemic respiratory failure (e.g., acute respiratory distress syndrome [ARDS]) currently represents the main indication for high-flow veno-venous-extracorporeal membrane oxygenation. On the other hand, lower-flow extracorporeal carbon dioxide removal might potentially help to avoid or attenuate ventilator-induced lung injury by allowing reduction of the energy load (i.e., driving pressure, mechanical power) transmitted to the lungs during mechanical ventilation or spontaneous ventilation. In the latter context, extracorporeal carbon dioxide removal plays an emerging role in the treatment of chronic obstructive pulmonary disease patients during acute exacerbations. Both applications of extracorporeal lung support raise important ethical considerations, such as likelihood of ultimate futility and end-of-life decision-making. The review concludes with a brief overview of potential technical developments and persistent challenges.
这篇综述重点介绍了在各种血流范围内使用静脉-静脉体外膜肺氧合治疗呼吸衰竭。首先简要概述了历史发展,讨论了体外循环期间气体交换(即氧合和脱羧)的生理学方面。解释了在日常临床实践中起着重要作用的再循环和分流等现象的机制。治疗难治性和有症状的低氧性呼吸衰竭(例如急性呼吸窘迫综合征[ARDS])目前是高流量静脉-静脉体外膜肺氧合的主要适应证。另一方面,较低流量的体外二氧化碳清除可能有助于通过降低机械通气或自主通气时传递到肺部的能量负荷(即驱动压、机械功率)来避免或减轻呼吸机引起的肺损伤。在后一种情况下,体外二氧化碳清除在急性加重期慢性阻塞性肺疾病患者的治疗中发挥着新兴作用。体外肺支持的这两种应用都引起了重要的伦理考虑,例如最终无效和临终决策的可能性。综述最后简要概述了潜在的技术发展和持续存在的挑战。